On Tuesday, Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was -5.27% drop from the session before settling in for the closing price of $18.61. A 52-week range for ARWR has been $9.57 – $30.41.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at 103.90%. With a float of $115.20 million, this company’s outstanding shares have now reached $138.06 million.
The firm has a total of 609 workers. Let’s measure their productivity. In terms of profitability, gross margin is 98.16%, operating margin of -21.74%, and the pretax margin is -27.93%.
Arrowhead Pharmaceuticals Inc (ARWR) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Arrowhead Pharmaceuticals Inc stocks. The insider ownership of Arrowhead Pharmaceuticals Inc is 16.58%, while institutional ownership is 74.56%. The most recent insider transaction that took place on Jul 10 ’25, was worth 761,709. Before that another transaction happened on Apr 11 ’25, when Company’s Chief Executive Officer sold 50,800 for $11.49, making the entire transaction worth $583,692. This insider now owns 3,921,255 shares in total.
Arrowhead Pharmaceuticals Inc (ARWR) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 103.90% per share during the next fiscal year.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Trading Performance Indicators
You can see what Arrowhead Pharmaceuticals Inc (ARWR) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.15. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.47. Likewise, its price to free cash flow for the trailing twelve months is 529.29.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.38, a number that is poised to hit -0.95 in the next quarter and is forecasted to reach -3.40 in one year’s time.
Technical Analysis of Arrowhead Pharmaceuticals Inc (ARWR)
Analysing the last 5-days average volume posted by the [Arrowhead Pharmaceuticals Inc, ARWR], we can find that recorded value of 1.65 million was lower than the volume posted last year of 1.85 million. As of the previous 9 days, the stock’s Stochastic %D was 70.21%.
During the past 100 days, Arrowhead Pharmaceuticals Inc’s (ARWR) raw stochastic average was set at 68.68%, which indicates a significant increase from 59.03% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.86 in the past 14 days, which was lower than the 0.89 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $15.93, while its 200-day Moving Average is $17.77. Now, the first resistance to watch is $18.50. This is followed by the second major resistance level at $19.36. The third major resistance level sits at $19.82. If the price goes on to break the first support level at $17.18, it is likely to go to the next support level at $16.72. Now, if the price goes above the second support level, the third support stands at $15.86.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Key Stats
There are 138,100K outstanding shares of the company, which has a market capitalization of 2.43 billion. As of now, sales total 3,550 K while income totals -599,490 K. Its latest quarter income was 542,710 K while its last quarter net income were 370,450 K.
